The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Q: My doctor heard a new heart murmur and suspected I have a narrowed valve due to aortic stenosis. I feel fine. Why did this ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...